🧪
hypothesis

APOE4-driven lysosome-to-ER cholesterol transport failure reduces ER-accessible cholesterol and releases SCAP-SREBP2 from ER retention

Hypothesis

APOE4-driven lysosome-to-ER cholesterol transport failure reduces ER-accessible cholesterol and releases SCAP-SREBP2 from ER retention

The strongest synthesis is an indirect mechanism in glia: APOE4 promotes cholesterol sequestration in late endosome/lysosome compartments, lowering the ER-accessible cholesterol pool sensed by SCAP despite normal or elevated total cellul.
🧬 NPC1🩺 molecular-biology🎯 Composite 74%💱 $0.59▼14.0%proposed
molecular biology
EvidencePending (0%)📖 0 cit🗣 1 debates 4 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.84 (15%) Evidence 0.79 (15%) Novelty 0.63 (12%) Feasibility 0.78 (12%) Impact 0.71 (12%) Druggability 0.58 (10%) Safety 0.42 (8%) Competition 0.68 (6%) Data Avail. 0.75 (5%) Reproducible 0.72 (5%) KG Connect 0.50 (8%) 0.741 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite74%

🧪 Overview

The strongest synthesis is an indirect mechanism in glia: APOE4 promotes cholesterol sequestration in late endosome/lysosome compartments, lowering the ER-accessible cholesterol pool sensed by SCAP despite normal or elevated total cellular cholesterol. This weakens SCAP-INSIG retention, increases SREBP2 processing, and may explain the paradox of cholesterol accumulation alongside increased cholesterol biosynthesis.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["NPC1 Protein<br/>Intracellular Cholesterol Transporter"]
    B["NPC1 Mutation<br/>Lysosomal Cholesterol Accumulation"]
    C["Late Endosome Maturation<br/>Esterified Cholesterol Trapped"]
    D["ER Calcium Dysregulation<br/>Store-Operated Entry"]
    E["Mitochondrial Cholesterol<br/>Mitochondrial Membrane Rigid"]
    F["Apoptosis Susceptibility<br/>Increased Neuronal Death"]
    G["Axonal Transport Deficit<br/>Microtubule Disruption"]
    H["Neurodegeneration<br/>Neuronal Loss in NPC Disease"]
    I["Cognitive Decline<br/>Neurofibrillary Tangles"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    G --> H
    H --> I
    style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style I fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix4 supports3 contradicts
Supports
APOE4 glia show lysosomal cholesterol accumulation and altered cholesterol homeostasis consistent with compartmental misrouting rather than simple cholesterol deficiency.
PMID:35750033
Supports
Recent data support APOE4-associated cholesterol sequestration and glial lipid trafficking defects relevant to ER sterol sensing.
PMID:37777962
Supports
ER-accessible cholesterol is the key regulatory pool controlling SCAP-SREBP retention and SREBP activation.
PMID:28841344
Supports
NPC-like lysosomal export failure is known to impair ER feedback and sustain SREBP activation.
PMID:31537798
Contradicts
No study directly demonstrates the full APOE4-to-NPC1/ER-contact-to-SCAP causal chain in human glia.
PMID:31537798
Contradicts
Lysosomal cholesterol accumulation could be secondary to broader autophagy or stress defects rather than the primary driver of SREBP2 activation.
PMID:35750033
Contradicts
Therapeutic cholesterol mobilizers such as cyclodextrins are pleiotropic and carry significant safety liabilities including ototoxicity risk.
PMID:28803710
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — NPC1

No curated PDB or AlphaFold mapping for NPC1 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for NPC1 from GTEx v10.

Spinal cord cervical c-142.6 Substantia nigra14.4 Hippocampus13.7 Putamen basal ganglia11.6 Caudate basal ganglia10.3 Hypothalamus9.3 Amygdala9.2 Cerebellum8.5 Frontal Cortex BA98.3 Cerebellar Hemisphere8.1 Cortex7.9 Nucleus accumbens basal ganglia6.9 Anterior cingulate cortex BA246.6median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for NPC1 →

No DepMap CRISPR Chronos data found for NPC1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Falling
7d Momentum
▼ 1.3%
Volatility
Low
0.0109
Events (7d)
3
Price History
▼14.0%

💾 Resource Usage

LLM Tokens
17,104
$0.0513
Total Cost
$0.0513

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF ER-localized cholesterol is measured directly using an ER-targeted cholesterol biosensor (ER-CholeMIM) in live APOE4 versus APOE3 astrocytes, THEN APOE4 astrocytes will exhibit ≥35% lower ER cholesER cholesterol concentration significantly lower in APOE4 (≥35% reduction); total cellular cholesterol unchanged between genotypes— no observation —pending0.68
IF cyclodextrin-mediated enhancement of cytosolic cholesterol trafficking to the ER is applied to APOE4 homozygous iPSC-derived astrocytes, THEN SREBP2 cleavage (nuclear SREBP2/total SREBP2 ratio) wilnuclear SREBP2 protein levels decrease ≥40%; HMG-CoA reductase activity normalized to APOE3 baseline— no observation —pending0.72
🔮 Falsifiable Predictions (2)
pendingconf 72%
IF cyclodextrin-mediated enhancement of cytosolic cholesterol trafficking to the ER is applied to APOE4 homozygous iPSC-derived astrocytes, THEN SREBP2 cleavage (nuclear SREBP2/total SREBP2 ratio) will decrease by ≥40% within 6 hours post-treatment, and total HMG-CoA reductase activity will normaliz
Predicted outcome: nuclear SREBP2 protein levels decrease ≥40%; HMG-CoA reductase activity normalized to APOE3 baseline
Falsification: SREBP2 processing remains elevated (change <20%) or increases further despite enhanced cholesterol delivery to the cytosol, indicating the transport defect is downstream of cytosolic redistribution
pendingconf 68%
IF ER-localized cholesterol is measured directly using an ER-targeted cholesterol biosensor (ER-CholeMIM) in live APOE4 versus APOE3 astrocytes, THEN APOE4 astrocytes will exhibit ≥35% lower ER cholesterol concentration despite no difference in total cellular cholesterol content, with this differenc
Predicted outcome: ER cholesterol concentration significantly lower in APOE4 (≥35% reduction); total cellular cholesterol unchanged between genotypes
Falsification: ER cholesterol concentration is equal or higher in APOE4 versus APOE3 cells, or NPC1 overexpression fails to increase ER cholesterol in APOE4 cells, disproving the lysosomal sequestration mechanism
View on SciDEX ↗